Skip to main content
Journal cover image

Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.

Publication ,  Journal Article
Todd, CS; Deese, J; Wang, M; Hubacher, D; Steiner, MJ; Otunga, S; Van Damme, L; FEM-PrEP Study Group
Published in: Contraception
March 2015

OBJECTIVE: The objective was to assess associations between tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) exposure and levonorgestrel (LNG) concentrations among Kenyan HIV prevention trial participants using Sino-implant (II) LNG implants for contraception. METHODS: Women were offered implants among other contraceptive methods, were randomized to daily TDF-FTC or placebo, and followed monthly up to 56weeks. Associations between TDF-FTC exposure and mean LNG values were analyzed with linear mixed models. RESULTS: Of 739 women, 29 (3.9%) received implants with no incident pregnancies and one discontinuation. Mean LNG concentrations over 56weeks among 28 women contributing data ranged between 214.0 and 659.8pg/mL with no significant difference between TDF-FTC and placebo arms or between variable levels of TDF-FTC adherence. CONCLUSION: Concomitant TDF-FTC use was not associated with a significant change in plasma LNG concentrations among women using Sino-implant (II) in the first year of use.

Duke Scholars

Published In

Contraception

DOI

EISSN

1879-0518

Publication Date

March 2015

Volume

91

Issue

3

Start / End Page

248 / 252

Location

United States

Related Subject Headings

  • Young Adult
  • Tenofovir
  • Prospective Studies
  • Polypharmacy
  • Organophosphonates
  • Obstetrics & Reproductive Medicine
  • Longitudinal Studies
  • Levonorgestrel
  • Kenya
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Todd, C. S., Deese, J., Wang, M., Hubacher, D., Steiner, M. J., Otunga, S., … FEM-PrEP Study Group. (2015). Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya. Contraception, 91(3), 248–252. https://doi.org/10.1016/j.contraception.2014.10.008
Todd, Catherine S., Jennifer Deese, Meng Wang, David Hubacher, Markus J. Steiner, Sheila Otunga, Lut Van Damme, and FEM-PrEP Study Group. “Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.Contraception 91, no. 3 (March 2015): 248–52. https://doi.org/10.1016/j.contraception.2014.10.008.
Todd, Catherine S., et al. “Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.Contraception, vol. 91, no. 3, Mar. 2015, pp. 248–52. Pubmed, doi:10.1016/j.contraception.2014.10.008.
Todd CS, Deese J, Wang M, Hubacher D, Steiner MJ, Otunga S, Van Damme L, FEM-PrEP Study Group. Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya. Contraception. 2015 Mar;91(3):248–252.
Journal cover image

Published In

Contraception

DOI

EISSN

1879-0518

Publication Date

March 2015

Volume

91

Issue

3

Start / End Page

248 / 252

Location

United States

Related Subject Headings

  • Young Adult
  • Tenofovir
  • Prospective Studies
  • Polypharmacy
  • Organophosphonates
  • Obstetrics & Reproductive Medicine
  • Longitudinal Studies
  • Levonorgestrel
  • Kenya
  • Humans